Pharmacology Biochemical Pharmacology

12-HETE and BLT2 Drive Pulmonary Hypertension Remodelling; 12/15-LOX Inhibitor Helps in SuHx Mice

  • Plasma 12-HETE was higher in patients with pulmonary arterial hypertension.
  • In the SU5416/hypoxia mouse model, the 12/15-LOX inhibitor ML-351 slowed disease progression.
  • Single-cell data suggested a subset of smooth muscle cells transdifferentiates into eosinophil-like cells that, with native eosinophils, secrete 12-HETE; the BLT2 antagonist LY255283 curbed hypoxic smooth muscle proliferation.
Points Based on the abstract

Two druggable nodes, 12/15-LOX and BLT2, make this a tidy target story, but SuHx mice are a weak predictor of clinical PAH and ML-351 is a tool compound with limited exposure data. The eosinophil-like transdifferentiation is the novel claim and needs lineage tracing, not scRNA-seq inference alone, before I'd build on it.